486 related articles for article (PubMed ID: 15767641)
1. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.
Pao W; Miller VA
J Clin Oncol; 2005 Apr; 23(11):2556-68. PubMed ID: 15767641
[TBL] [Abstract][Full Text] [Related]
2. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
Mu XL; Li LY; Zhang XT; Wang MZ; Feng RE; Cui QC; Zhou HS; Guo BQ
Clin Cancer Res; 2005 Jun; 11(12):4289-94. PubMed ID: 15958609
[TBL] [Abstract][Full Text] [Related]
3. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
Riely GJ; Pao W; Pham D; Li AR; Rizvi N; Venkatraman ES; Zakowski MF; Kris MG; Ladanyi M; Miller VA
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):839-44. PubMed ID: 16467097
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
5. The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations.
Riely GJ
Lung Cancer; 2008 Jun; 60 Suppl 2():S19-22. PubMed ID: 18513580
[TBL] [Abstract][Full Text] [Related]
6. EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects.
Soria JC; Mok TS; Cappuzzo F; Jänne PA
Cancer Treat Rev; 2012 Aug; 38(5):416-30. PubMed ID: 22119437
[TBL] [Abstract][Full Text] [Related]
7. Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa).
Siegel-Lakhai WS; Beijnen JH; Schellens JH
Oncologist; 2005 Sep; 10(8):579-89. PubMed ID: 16177282
[TBL] [Abstract][Full Text] [Related]
8. Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib.
Heigener DF; Reck M
Adv Ther; 2011 Feb; 28(2):126-33. PubMed ID: 21181318
[TBL] [Abstract][Full Text] [Related]
9. Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Di Maio M; Gridelli C; Normanno N; Perrone F; Ciardiello F
J Cell Physiol; 2005 Dec; 205(3):355-63. PubMed ID: 15895392
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI.
Uramoto H; Yamada T; Yano S; Kondo N; Hasegawa S; Tanaka F
Anticancer Res; 2012 Sep; 32(9):3785-90. PubMed ID: 22993320
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese.
Uramoto H; Sugio K; Oyama T; Ono K; Sugaya M; Yoshimatsu T; Hanagiri T; Morita M; Yasumoto K
Lung Cancer; 2006 Jan; 51(1):71-7. PubMed ID: 16198442
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.
Roengvoraphoj M; Tsongalis GJ; Dragnev KH; Rigas JR
Cancer Treat Rev; 2013 Dec; 39(8):839-50. PubMed ID: 23768755
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.
Bell DW; Lynch TJ; Haserlat SM; Harris PL; Okimoto RA; Brannigan BW; Sgroi DC; Muir B; Riemenschneider MJ; Iacona RB; Krebs AD; Johnson DH; Giaccone G; Herbst RS; Manegold C; Fukuoka M; Kris MG; Baselga J; Ochs JS; Haber DA
J Clin Oncol; 2005 Nov; 23(31):8081-92. PubMed ID: 16204011
[TBL] [Abstract][Full Text] [Related]
14. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.
Sequist LV; Bell DW; Lynch TJ; Haber DA
J Clin Oncol; 2007 Feb; 25(5):587-95. PubMed ID: 17290067
[TBL] [Abstract][Full Text] [Related]
15. Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer.
Tokumo M; Toyooka S; Ichihara S; Ohashi K; Tsukuda K; Ichimura K; Tabata M; Kiura K; Aoe M; Sano Y; Date H; Shimizu N
Lung Cancer; 2006 Jul; 53(1):117-21. PubMed ID: 16730855
[TBL] [Abstract][Full Text] [Related]
16. Erlotinib in the first-line treatment of non-small-cell lung cancer.
D'Arcangelo M; Cappuzzo F
Expert Rev Anticancer Ther; 2013 May; 13(5):523-33. PubMed ID: 23617344
[TBL] [Abstract][Full Text] [Related]
17. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Jänne PA; Johnson BE
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
[TBL] [Abstract][Full Text] [Related]
18. Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors.
Haber DA; Bell DW; Sordella R; Kwak EL; Godin-Heymann N; Sharma SV; Lynch TJ; Settleman J
Cold Spring Harb Symp Quant Biol; 2005; 70():419-26. PubMed ID: 16869779
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancer.
Kitamura A; Hosoda W; Sasaki E; Mitsudomi T; Yatabe Y
Clin Cancer Res; 2010 Jul; 16(13):3349-55. PubMed ID: 20570926
[TBL] [Abstract][Full Text] [Related]
20. Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery.
Kondo M; Yokoyama T; Fukui T; Yoshioka H; Yokoi K; Nagasaka T; Imaizumi K; Kume H; Hasegawa Y; Shimokata K; Sekido Y
Lung Cancer; 2005 Dec; 50(3):385-91. PubMed ID: 16140420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]